Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TG Therapeutics (TGTX)

TG Therapeutics reports Q3 net income of $113.9 million on $165.8 million revenue

Positive Impact 3 of 5 earnings Written later

TG Therapeutics reported results for the third quarter ended September 30, 2023, with total revenue of $165.8 million, of which $140.0 million was a one-time payment from Neuraxpharm. The company reported net income of $113.9 million, compared with a net loss of $35.8 million a year earlier, and said cash, cash equivalents and investment securities were $229.2 million at quarter end.

Key points

  • Q3 2023 total revenue of $165.8 million, including $140.0 million of license revenue tied to a one-time Neuraxpharm payment received in July 2023
  • BRIUMVI U.S. net sales of $25.1 million in Q3 2023, up from $0.1 million in Q3 2022
  • Q3 2023 net income of $113.9 million, or $0.80 per basic share, versus a net loss of $35.8 million in Q3 2022
  • Cash, cash equivalents and investment securities of $229.2 million as of September 30, 2023

The filing

CompanyTG Therapeutics (TGTX)
Form8-K, current report
Filed with the SECNov 1, 2023, 7:33 AM ET
Accession number0001437749-23-029660

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 01, 2023.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.